SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)--
Santarus,
Inc. SNTS and Pharming
Group NV PHARM today announced that their pivotal
Phase III clinical study to evaluate the safety and efficacy of the
investigational drug RUCONEST® (recombinant human C1 esterase
inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in
patients with Hereditary Angioedema (HAE) met the primary endpoint of
time to beginning of symptom relief.
A statistically significant difference in the time to beginning of
symptom relief was observed in the intent-to-treat population (n=75)
between RUCONEST and placebo (p=0.031, log-rank test); the median time
to beginning of symptom relief was 90 minutes for RUCONEST patients
(n=44) and 152 minutes
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in